Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Choline Alfoscerate and Donepezil in Alzheimer's with Cerebrovascular Injury
NCT02648906Phase 4Unknown
- Sponsor
- Daewoong Pharmaceutical
- Start
- Jul 2015
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Alzheimer's disease (AD) comparing Choline alfoscerate + Donepezil with Placebo + Donepezil (2 arms). Primary endpoint: Alzheimer's Disease Assessment Scale-Cognitive Subscale at 48 weeks. Status: unknown.
02
Drugs
choline alfoscerate
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02648906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02648906.